Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Lung Cancer: Tumor Progression and Target Therapy"
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Therapeutics".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 10919
Special Issue Editors
Interests: lung diseases; lung cancer; interstitial lung diseases
Interests: biochemistry; genetics and molecular biology; cancer therapeutics; lung cancer stem cells
Special Issue Information
Lung cancer is one of the leading causes of cancer death worldwide. Among all lung cancer histotypes, about 85% of cases are represented by non-small cell lung carcinomas (NSCLC). Although great progress has been made in recent decades in the knowledge of its biology and the mechanisms of tumor progression, particularly for the adenocarcinoma histotype, lung tumors still represent a challenge. The demonstration of mutations in genes involved in the growth of the tumor cell has allowed the development of target therapy (as small molecule tyrosine kinase inhibitors). In particular, mutations have been identified in v-Ki-ras2 Kristen rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR) BRAF, and the parallel PI3K pathway oncogene. More recently, interest has focused on MEK and HER2 and the rearrangements of ALK and ROS1. Amplifications of oncogenes such as MET in adenocarcinomas and of FGFR and discoidin domain receptor 2 (DDR2) in squamous carcinomas are under investigation for therapeutic intervention. In addition, immunotherapy has allowed new and unexpected benefits on the survival of selected patients.
As a consequence, such knowledge has resulted in a revolution in the diagnosis and treatment of pulmonary adenocarcinomas based on the genotype or an individual’s tumor.
The aim of the present Special Issue will be focused on well-designed studies and research able to improve our knowledge of lung cancer, our understanding of the mechanisms underlying tumor initiation, propagation, and progression, and ameliorate the influence or change direction in lung cancer diagnosis and therapy. As a consequence, these works may give the basis for novel therapeutic approaches, early or more specific diagnostic procedures. Not only clinical but also basic science research is encouraged. In addition, works aiming to translate basic knowledge into the clinic, such as treatment and prevention, diagnosis, and novel therapeutic modalities, will be also considered. Articles in this Special Issue may include reviews and researcher papers. The issue comprehensively covers many areas of interest and could be of interest to a broad range of readers, including physicians, scientists, students, and pharmaceutical companies.
Prof. Dr. Alberto Ricci
Prof. Dr. Rita Mancini
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- lung cancer
- target mutation
- target therapy
- medical imaging